Chardan Capital Keeps a Buy Rating on Replimune Group Inc (REPL)
In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Replimune Group Inc (REPL), with a price target of $28.00. The company’s shares closed last Monday at $13.03.
According to TipRanks.com, Livshits is ranked 0 out of 5 stars with an average return of -14.1% and a 20.7% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Logicbio Therapeutics Inc, and Crispr Therapeutics AG.
Currently, the analyst consensus on Replimune Group Inc is a Strong Buy with an average price target of $24.67, a 99.3% upside from current levels. In a report issued on September 30, H.C. Wainwright also reiterated a Buy rating on the stock with a $26.00 price target.
See today’s analyst top recommended stocks >>
Based on Replimune Group Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $9.51 million. In comparison, last year the company had a GAAP net loss of $6.46 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.